Larson Financial Group
KYTX icon

Larson Financial Group’s Kyverna Therapeutics KYTX Stock Holding History

Larson Financial Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-40
Closed -$356 – 4039
2026
Q2 		$356 Hold
40
– – ﹤0.01% 3548
2026
Q1 		$345 Buy
+40
New +$333 ﹤0.01% 3384

Other funds holding KYTX

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ACPLP
ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Larson Financial Group's KYTX Position: Q3 2026 in Review

Larson Financial Group sold out of Kyverna Therapeutics (KYTX) in Q3 2026, closing a stake of 40 shares — an estimated $356 sold.

Larson Financial Group first reported a position in KYTX in Q1 2026 and held it in 2 quarters. The position peaked at $356 in Q2 2026. 41 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

  • Larson Financial Group reported no remaining Kyverna Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Larson Financial Group sold 40 Kyverna Therapeutics shares in Q3 2026, an estimated $356.
  • Larson Financial Group first reported a position in Kyverna Therapeutics in Q1 2026 and held it in 2 quarters.
  • Larson Financial Group's Kyverna Therapeutics position peaked at $356 in Q2 2026.
  • 41 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.